World Journal of *Psychiatry*

World J Psychiatry 2024 December 19; 14(12): 1783-1991





Published by Baishideng Publishing Group Inc

JP World Journal of Psychiatry

Contents

Monthly Volume 14 Number 12 December 19, 2024

EDITORIAL

1783 Diminishing restrictive practices in psychiatric wards *via* virtual reality training: Old wine in a new bottle? Zeng Y, Zhang JW, Yang J 1788 Optimizing anesthesia depth to enhance seizure quality during electroconvulsive therapy in major depressive disorder

Byeon H

Embracing the complexity of lived experiences in psychiatry research: Reflexivity, cultural sensitivity, and 1793 emergent design

Xiao ZS, Zhou H, Jiang YL, Samah NA

MINIREVIEWS

1797 Depression and anxiety disorders in chronic obstructive pulmonary disease patients: Prevalence, disease impact, treatment

Qiu CJ, Wu S

ORIGINAL ARTICLE

Case Control Study

1804 Interaction between serum inflammatory cytokines and brain-derived neurotrophic factor in cognitive function among first-episode schizophrenia patients

Cui LJ, Cai LL, Na WQ, Jia RL, Zhu JL, Pan X

Retrospective Study

1815 Trends and prevalence of eating disorders in children and adolescents

Chen Q, Huang S, Peng JY, Xu H, Wang P, Shi XM, Li SQ, Luo R, Zhang W, Shi L, Peng Y, Wang XH, Tang XW

- 1827 Correlation between self-efficacy, parental parenting patterns, and severe depression in adolescents Zhang BF, Zhang XY
- 1836 Depression and anxiety, peripheral blood inflammatory factors, and stress levels on therapeutic outcomes in patients with chronic wounds

Li B, Li C, Zhong XJ, Xu XR

1845 Influence of preoperative comprehensive education on anxiety, depression, pain, and sleep in elderly patients operated under general anesthesia

Qu L, Ma R, Ma YK, Zhao X, Jin J, Zhu QQ, Chen XY, Xu GP

1854 Impact of solution-focused brief therapy and vacuum sealing drainage on mental health of wound care patients

Shi WJ, Zhou J, Xu QL, Jiang Y, Dai Q



World Journal of Psychiati	
Conten	Monthly Volume 14 Number 12 December 19, 2024
1860	Wuling capsule combined with sertraline in the therapy of anxiety and depression with insomnia in adolescents
	Duo LL, Rao GF
1868	Relationship between gestational body mass index, blood pressure variability, and postpartum depression in pregnant women with pre-eclampsia
	Wu FF, Xu H
1876	Mindfulness-based stress reduction training and supplemented Jinshui Liujun decoction promote recovery in patients with non-small cell lung cancer
	Liu DW, Zhou XA, Wu XY, Wang YX, Fan JT, Li ZL
	Clinical Trials Study
1886	Music therapy combined with motivational interviewing
	Meng DF, Bao J, Cai TZ, Ji YJ, Yang Y
1892	Effects of remote support courses on parental mental health and child development in autism: A randomized controlled trial
	Lu JH, Wei H, Zhang Y, Fei F, Huang HY, Dong QJ, Chen J, Ao DQ, Chen L, Li TY, Li Y, Dai Y
	Observational Study
1905	Analysis of anxiety and depression status and their influencing factors in patients with diabetic retinopathy
	Gao S, Liu X
1918	Impact of anxiety symptoms on dialysis adherence and complication rates: A longitudinal observational study
	Huang P, Huang HT, Ma J, Pang J, Zhang YY, Ma CH, Wang SD, Liang XZ, Wang J
1925	Predictive value of nutritional status and serological indicators in elderly patients with mild cognitive impairment
	Yang Y, Lu SR, Xu Q, Yu J, Wang Z, Zhang BS, Hong K
	Prospective Study
1936	Network analysis of adolescent non-suicidal self-injury subgroups identified through latent profile analysis
	Yang W, Lian K, Cheng YQ, Xu XF, Duan XC, You X
	Randomized Controlled Trial
1947	Effect of comprehensive intervention model based on drug-psychology-society-skills on medication compliance and cognitive ability of chronic schizophrenia patients
	Wang HJ, Chen W, Yan XL, Huang QY, Xu WD
	META-ANALYSIS
1956	Association of premature birth and maternal education level on attention deficit hyperactivity disorder in children: A meta-analysis

Zhao YK, Li M, Shi TT, Feng MM, Hu LL



Contents

Monthly Volume 14 Number 12 December 19, 2024

SCIENTOMETRICS

1971 Bibliometric and visual study of narcolepsy from 2000 to 2023

Yang C, Sun LL, Wang S, Li H, Zhang K

CASE REPORT

1982 Effect of bright-light therapy on depression and anxiety of a patient with Alzheimer's disease combined with sleep disorder: A case report

Mei X, Zou CJ, Zheng CY, Hu J, Zhou DS

LETTER TO THE EDITOR

1988 Heart abnormality associates with a wide spectrum of psychiatric disorders: Evidence from Mendelian randomization analyses

Chen XS, Song ZY, Chen XL, Bo YM, Li LL



Contents

Monthly Volume 14 Number 12 December 19, 2024

ABOUT COVER

Editorial Board Member of World Journal of Psychiatry, Hsien-Yuan Lane, MD, PhD, Professor, Chief, Department of Psychiatry, China Medical University, Taichung 404328, Taiwan. hylane@gmail.com

AIMS AND SCOPE

The primary aim of World Journal of Psychiatry (WJP, World J Psychiatry) is to provide scholars and readers from various fields of psychiatry with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJP mainly publishes articles reporting research results and findings obtained in the field of psychiatry and covering a wide range of topics including adolescent psychiatry, biological psychiatry, child psychiatry, community psychiatry, ethnopsychology, psychoanalysis, psychosomatic medicine, etc.

INDEXING/ABSTRACTING

The WJP is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for WJP as 3.9; JIF without journal self cites: 3.8; 5-year JIF: 3.7; JIF Rank: 58/279 in psychiatry; JIF Quartile: Q1; and 5-year JIF Quartile: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hna-Ge Yu; Production Department Director: Xu Guo; Cover Editor: Jia-Ping Yan.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Psychiatry	https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 2220-3206 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
December 31, 2011	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Monthly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Ting-Shao Zhu	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/2220-3206/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE December 19, 2024	STEPS FOR SUBMITTING MANUSCRIPTS https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2024 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: office@baishideng.com https://www.wjgnet.com



WJP World Journal of Psychiatry

Submit a Manuscript: https://www.f6publishing.com

World J Psychiatry 2024 December 19; 14(12): 1797-1803

DOI: 10.5498/wjp.v14.i12.1797

ISSN 2220-3206 (online)

MINIREVIEWS

Depression and anxiety disorders in chronic obstructive pulmonary disease patients: Prevalence, disease impact, treatment

Chang-Jian Qiu, Shuang Wu

Specialty type: Psychiatry

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification Scientific Quality: Grade A Novelty: Grade A Creativity or Innovation: Grade A Scientific Significance: Grade B

P-Reviewer: Hasibuzzaman MA

Received: September 10, 2024 Revised: September 27, 2024 Accepted: October 25, 2024 Published online: December 19, 2024 Processing time: 77 Days and 20

Hours



Chang-Jian Qiu, Shuang Wu, Department of Psychiatry, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Corresponding author: Chang-Jian Qiu, MD, Doctor, Department of Psychiatry, West China Hospital, Sichuan University, No. 28 Telecom South Street, Wuhou District, Chengdu 610041, Sichuan Province, China. asd1827sci@163.com

Abstract

Chronic obstructive pulmonary disease (COPD) is a common respiratory disorder that often co-occurs with depression and anxiety, worsening disease progression and reducing quality of life. A thorough review of the existing literature was conducted, including searches in PubMed, Embase, PsycINFO, and Cochrane Library databases up to 2024. This review encompasses a critical analysis of studies reporting on the prevalence, impact, and management of depression and anxiety in COPD patients. We found a high prevalence of psychological comorbidities in COPD patients, which were associated with worse disease outcomes, including increased exacerbations, hospitalizations, and reduced health-related quality of life. Diagnosing and managing these conditions is complex due to overlapping symptoms, necessitating a comprehensive patient care approach. While there has been progress in understanding COPD comorbidities, there is a need for more personalized and integrated treatments. This review emphasizes the need for increased awareness, tailored treatment plans, and further research for effective interventions.

Key Words: Chronic obstructive pulmonary disease; Depression; Anxiety; Comorbidities; Treatment strategies; Narrative review

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Chronic obstructive pulmonary disease (COPD) is a global respiratory condition that affects public health. Depression and anxiety often accompany COPD, which can worsen the disease and lower patient quality of life. This narrative review examines COPD patients' depression and anxiety rates, their effects on disease progression, and current treatment options.

WJP | https://www.wjgnet.com

Citation: Qiu CJ, Wu S. Depression and anxiety disorders in chronic obstructive pulmonary disease patients: Prevalence, disease impact, treatment. World J Psychiatry 2024; 14(12): 1797-1803 URL: https://www.wjgnet.com/2220-3206/full/v14/i12/1797.htm DOI: https://dx.doi.org/10.5498/wjp.v14.i12.1797

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory disorder characterized by airflow obstruction, often stemming from chronic bronchitis or emphysema[1]. It poses a significant threat to public health, with a high prevalence rate of 9% to 10% among individuals over the age of 40 worldwide[2-4]. COPD diminishes patient quality of life and imposes a substantial economic burden on families and healthcare systems[5].

The etiology of COPD is not fully understood but is generally associated with chronic bronchitis and emphysema^[5]. Risk factors include environmental exposures such as smoking, dust, chemicals, respiratory infections, air pollution, and lower socioeconomic status, as well as individual factors like genetic predispositions and developmental issues during critical periods. Patients exhibit a range of symptoms including chronic cough, sputum production, shortness of breath, chest tightness, wheezing, fatigue, and weight loss[6]. COPD is a complex disease primarily caused by exposure to toxic particles or gases, leading to abnormalities in the airways and/or alveoli. It affects the lungs, the cardiovascular, nervous, endocrine, and mental health systems, resulting in complications such as asthma, lung cancer, diffuse pulmonary fibrosis, pulmonary hypertension, right-sided heart failure, diabetes, gastroesophageal reflux disease, depression, and anxiety[7, 8]. Among these, depression and anxiety are the most common comorbidities, often underdiagnosed due to overlapping symptoms[9]. The overlap between physical and mental symptoms complicates the diagnostic process and necessitates a comprehensive approach to patient care[10].

This review aims to delve into the prevalence of anxiety disorders in COPD patients and scrutinize the profound impact of depression and anxiety on disease progression. By synthesizing current research and treatment strategies, we aim to shed light on the importance of addressing these psychological comorbidities in clinical practice, thereby enhancing patient care and improving outcomes.

CURRENT STATUS OF DEPRESSION AND ANXIETY DISORDERS IN COPD PATIENTS

Prevalence and symptoms of depression and anxiety

Depression is a debilitating disorder that affects both the physiological and psychological well-being of individuals, often leading to a sense of helplessness and an increased risk of suicidal tendencies. Individuals with depression exhibit a loss of interest in activities they once enjoyed, impaired social relationships, and a range of other symptoms including sleep disturbances, fatigue, difficulty concentrating, and disordered eating patterns. The World Health Organization (WHO) recognizes major depressive disorder as one of the leading contributors to the global burden of disease[11]. In the context of comorbid physical illnesses, particularly chronic and severe conditions, the prevalence of major depressive disorder ranges from 10% to 20% [12-15]. Anxiety disorders, characterized by feelings of fear, avoidance, and restlessness, often cooccur with depression, exacerbating the complexity of the conditions[16,17]. The coexistence of depression and anxiety is more common than either disorder in isolation, and individuals with chronic illnesses such as COPD are 2 to 3 times more likely to experience depression compared to the general population matched for age and sex[12,18,19].

Prevalence of depression and anxiety in COPD patients

Depression is a common comorbidity in adult COPD patients, with an estimated prevalence of 24.6% [20]. The incidence of anxiety and depressive disorders in COPD patients is significantly higher, primarily associated with damage to the central nervous system and the chronic experience of negative emotions in COPD^[21]. The likelihood of a COPD patient developing comorbid depression is four times higher than that of an individual without COPD[21]. Furthermore, patients with other chronic conditions such as arthritis, cancer, diabetes, hypertension, and stroke are twice as likely to develop depression compared to those without these conditions^[22]. Among many chronic diseases, the incidence of depression is significantly higher in women than in men^[23], and this disparity is also observed in COPD patients, where the proportion of women with comorbid depression is notably higher than that of men[24].

Analysis of anxiety factors in patients with COPD

COPD causes organ damage but also inflicts psychological harm on patients, who can often exhibit various psychological abnormalities, predominantly characterized by anxiety, irritability, and depression[25]. Studies have indicated that the incidence of comorbid anxiety in COPD patients ranges from 50% to 75% [26]. Psychological disorders significantly impair patient recovery and quality of life and are one of the major factors leading to patient mortality[27]. Consequently, numerous clinical researchers are dedicated to analyzing the causes of anxiety in COPD patients. Through the analysis and summary of patient onset factors, effective measures can be taken to intervene, thereby improving the psychological state of patients and promoting faster recovery to health. For instance, Song et al[28] conducted a study on elderly patients with COPD to explore the best psychological nursing plan using anxiety and depression scales to identify the main factors affecting patient anxiety and depressive emotions. The study found that factors influencing anxiety in COPD



WJP | https://www.wjgnet.com

patients include occupation, education level, economic status, family relationships, and disease severity. Effective psychological nursing interventions based on these factors have been developed to improve patient psychological conditions, leading to a significant improvement in anxiety and depressive symptoms and promoting faster patient recovery.

Lokesh et al^[29] selected 100 patients with COPD for anxiety and depression scale assessment and found that the incidence of anxiety and depression in COPD patients was 65% and 54%, respectively. Patients who were more aware of their condition had poorer quality of life and more severe anxiety and depression. Living alone was identified as a significant factor contributing to patient anxiety, with males being more prone to anxiety than females. Therefore, if patients are diagnosed with symptoms of anxiety or depression, timely diagnosis and effective treatment measures should be taken to improve patient quality of life and prognosis.

Wu et al[30] studied related factors of patients with COPD and comorbid anxiety and depression disorders and found that the higher the quality of life assessment test score, the higher the probability of comorbid anxiety and depression. Patients without medical insurance and with longer disease courses had a higher probability of anxiety, more hospital admissions, and lower quality of life. Therefore, the clinical treatment of COPD patients with comorbid anxiety should be emphasized.

Cao et al[31] found that due to the chronic and protracted nature of COPD, patients experience a continuous decline in lung function and activity tolerance, reduced labor capacity, and decreased quality of life. The long-term medical treatment places a heavy economic burden on patients, often leading to negative psychological states such as hopelessness, apathy, inferiority, self-blame, and anxiety. Psychological counseling is an effective measure in treating anxiety and depression, and pharmacological treatment (e.g., with Dailixin) is also noteworthy for its ability to alleviate anxiety and depressive emotions and control the disease.

IMPACT OF DEPRESSION AND ANXIETY ON COPD

Influence on disease course

A comprehensive meta-analysis by Atlantis et al^[32] examined 22 studies, substantiating the bidirectional relationship between depression, anxiety, and COPD. Sixteen of these studies, encompassing 28759 patients followed for 1 year to 8 years, were utilized to predict the impact of depression and anxiety on COPD outcomes. Conversely, six studies, including 7439159 patients, investigated the influence of COPD on the incidence of depression and anxiety. The findings indicate that depression and anxiety significantly increase the risk of adverse COPD outcomes [relative risk (RR) = 1.43; 95%CI: 1.22-1.68], with a pronounced effect in patients under the age of 66. Comorbid depression augments the risk of mortality in COPD (RR = 1.83; 95% CI: 1.00-3.36), particularly among males. In the majority of studies, anxiety (or psychological stress) raised the risk of COPD exacerbation or death (RR = 1.27; 95% CI: 1.02-1.58). Furthermore, COPD elevated the risk of developing depression (RR = 1.83; 95%CI: 1.00-3.36).

Pooler et al[33] conducted a systematic review and meta-analysis of 24 studies, revealing that 17 studies (70.9%) provided evidence linking comorbid depression and anxiety with higher hospitalization and readmission rates due to COPD exacerbations. The analysis demonstrates that patients with comorbid depression and anxiety, once hospitalized, have longer hospital stays and a higher risk of mortality post-discharge[34].

Mathew et al[35] performed a single laboratory assessment of 37 COPD patients, including 17 current daily smokers and 20 former smokers. Participants completed self-report measures of psychological factors, impact of COPD symptoms, symptom response, and symptoms of anxiety and depression. Three psychological factors were evaluated: Anxiety sensitivity (AS), distress intolerance (DI), and anhedonia (Anh). In univariate regression models, AS, DI, and Anh were all correlated with severe COPD dyspnea symptoms. After adjusting for symptoms of generalized depression and anxiety, AS remained a significant predictor of dyspnea symptoms in COPD[36].

Impact on health-related quality of life

Enhancing health-related quality of life (HRQL) is a critical goal in the treatment of patients with chronic respiratory failure (CRF) undergoing long-term oxygen therapy and/or home non-invasive ventilation. A systematic review and meta-analysis included six studies to examine the association between comorbid depression and anxiety in COPD and HRQL[37]. The results indicate that comorbid depression at the 1-year follow-up is significantly correlated with HRQL (pooled r = 0.48, 95% CI: 0.37-0.57, P < 0.001). Similarly, comorbid anxiety at the 1-year follow-up was also significantly related to HRQL (pooled r = 0.36, 95% CI: 0.23-0.48, P < 0.001). A multicenter prospective cross-sectional study involving 80 severe COPD patients with an average age of 66 years and 93% male participants selected depression status, dyspnea, exacerbation frequency, and exercise capacity as predictors for the total St. George's Respiratory Questionnaire score. The findings suggest that the presence of comorbid depression is the strongest predictor of disease-specific and general HRQL. Screening and early intervention for depression in severe COPD patients can improve HRQL[38].

Recent evidence underscores the importance of comprehensive care in addressing the psychological comorbidities in COPD[16,19,31]. The use of remote patient monitoring (RPM) technologies has shown promise in helping patients selfmanage and reducing COPD-related hospital readmissions[28]. These technologies, which include devices like pulse oximeters and spirometers, can aid in the early recognition of COPD exacerbations, potentially leading to better disease management and improved HRQL[30]. Pulmonary rehabilitation, a key non-pharmacological intervention, has been shown to improve not only physical capacity but also mood symptoms in COPD patients. This holistic approach can be particularly beneficial in enhancing HRQL by reducing symptoms, optimizing functional status, and increasing patient participation. The integration of psychological support with medical management is crucial in enhancing HRQL for COPD patients. The adoption of RPM technologies and participation in pulmonary rehabilitation programs can provide

WJP https://www.wjgnet.com

additional benefits beyond traditional pharmacological treatments, offering a more comprehensive approach to care. The impact of depression and anxiety on COPD are summarized in Table 1.

TREATMENT STRATEGIES

When comorbid with COPD, depression and anxiety significantly impact patients' quality of life and functional outcomes. The WHO advocates for chronic disease patients, such as those with COPD, to receive patient-centered, comprehensive care plans that extend beyond disease-specific treatments^[39]. Therapeutic approaches for psychological symptoms in COPD patients typically include cognitive-behavioral therapy, pharmacological interventions, pulmonary rehabilitation, relaxation techniques, and palliative care.

Pharmacological interventions

The National Institute for Health and Care Excellence (NICE) guidelines for the treatment of depression in older adults recommend the use of antidepressant medications for moderate to severe depression, including in patients with COPD. Selective serotonin reuptake inhibitors (SSRIs) are suggested as the first-line treatment for depression and should be accompanied by appropriate depression rating scales, such as the Patient Health Questionnaire-9 or the Hospital Anxiety and Depression Scale^[40]. A subset of randomized clinical trials has confirmed the benefits of antidepressant treatment for patients with COPD and comorbid depression, not only reducing depressive symptoms but also decreasing tobacco dependence, improving subjective breathlessness, enhancing appetite, preventing weight loss, and alleviating anxiety symptoms[41]. Current pharmacological research for depression and anxiety in COPD patients primarily focuses on SSRIs and tricyclic antidepressants (TCAs). An evaluation of antidepressants, mainly SSRIs and TCAs, has shown significant improvement for patients with depression or depressive symptoms comorbid with physical illnesses. This assessment also demonstrated that SSRIs have a higher degree of long-term improvement compared to TCAs[42]. Therefore, SSRIs are the preferred treatment for depression and anxiety[43].

In a randomized controlled trial^[44] involving 120 patients with stable COPD and moderate to severe depression, there was no statistically significant difference in lung function test parameters between the placebo and intervention groups treated with sertraline (P > 0.05). However, patients in the sertraline group showed a greater change in the Hamilton Depression Scale scores and the COPD Assessment Test after treatment (P < 0.05), and they also walked a longer distance in the 6-minute walk test compared to the placebo group (P < 0.05). A single-blind study[45] followed 14 COPD patients with comorbid depression who took fluoxetine 20 mg daily for 6 months, with 7 completing the study. Among those who completed the study, 4 responded to fluoxetine (a 50% reduction in the Geriatric Mental State Schedule scores). After 6 months of fluoxetine treatment, there were no significant improvements in forced expiratory volume in 1 second or physical activity scores. A study [46] compared the efficacy of paroxetine (20 mg/day) with placebo in 28 COPD patients over 6 weeks. There were no statistically significant differences in exercise capacity, lung function, and quality of life between the two groups. After the 6-week open-label phase with paroxetine, both groups continued to take 20 mg paroxetine for an additional 3 months, resulting in significant improvements in depression scores, walking distance, and quality of life.

Potential drug interactions

In the management of COPD, β2-agonists and anticholinergic medications are frequently utilized. Notably, β2-agonists such as salbutamol, indacaterol, and salmeterol can lead to dose-dependent prolongation of the QT interval and potassium loss. The co-administration of these medications with certain SSRIs known to prolong the QT interval, such as escitalopram, citalopram, and fluoxetine, and TCAs like nortriptyline and dothiepin, may result in additive effects and an increased risk of ventricular arrhythmias^[47]. Furthermore, TCAs have the potential to exacerbate cardiovascular adverse effects associated with β 2-agonists, including hypertension, tachycardia, and chest pain. Additionally, the anticholinergic properties of TCAs can intensify the effects of anticholinergic bronchodilators used in COPD, such as tiotropium and ipratropium, leading to side effects like dry mouth, urinary retention, constipation, mydriasis, blurred vision, and fever, and potentially worsening glaucoma.

Non-pharmacological interventions

The NICE guidelines for depression in adults highlight the importance of psychosocial interventions for patients with chronic health conditions, including those with clinical or subthreshold depression. These interventions can range from low to high intensity, tailored to the severity of mood symptoms [48]. A systematic review of randomized controlled trials involving psychological and/or lifestyle interventions for adult COPD patients indicates that complex interventions, including an exercise component, significantly improve depressive and anxiety symptoms. Importantly, multicomponent exercise training can effectively alleviate anxiety and depressive symptoms in all COPD patients, irrespective of the severity of these conditions[49].

CONCLUSION

Current studies on treating depression and anxiety in COPD patients face limitations such as small sample sizes, diverse patient populations, and inconsistent assessment tools. These issues necessitate more rigorous validation through larger



WJP | https://www.wjgnet.com

Table 1 Impact of depression and anxiety on chronic obstructive pulmonary disease			
Disease impact	Details		
Bidirectional relationship	A significant bidirectional relationship between depression, anxiety, and COPD[32]		
Impact on COPD outcomes	Depression and anxiety significantly increase the risk of adverse COPD outcomes and mortality in COPD. Anxiety raises the risk of COPD exacerbation or death[32]		
Hospitalization and readmission rates	Higher hospitalization and readmission rates due to COPD exacerbations in patients with comorbid depression and anxiety[33]		
Psychological factors and dyspnea	Anxiety sensitivity to be a significant predictor of dyspnea symptoms in COPD, even after adjusting for generalized depression and anxiety[35]		
HRQL	Comorbid depression and anxiety at the 1-year follow-up are significantly correlated with HRQL in COPD[35]		
Predictors of HRQL	Comorbid depression as the strongest predictor of disease-specific and general HRQL in severe COPD patients[38]		

COPD: Chronic obstructive pulmonary disease; HRQL: Health-related quality of life.

randomized controlled trials to confirm treatment effectiveness. For patients with mild to moderate depression, nonpharmacological interventions like psychological therapy and lifestyle changes are recommended. These methods have shown efficacy in managing symptoms without medication-related risks. In severe cases where non-pharmacological approaches are inadequate, cautious use of antidepressants like SSRIs may be necessary. Regular ECG assessments are recommended to monitor for potential QT interval prolongation[30]. Patients should be informed about the importance of immediate medical attention for symptoms like palpitations or syncope, which could signal cardiac side effects. Regular monitoring of electrolyte levels is also crucial to prevent arrhythmias. The use of antidepressants requires careful consideration of potential drug interactions. Balancing the benefits of symptom relief against treatment risks is key, emphasizing the need for personalized treatment strategies tailored to each patient's specific needs. The findings highlight the importance of a multifaceted approach to managing depression and anxiety in COPD patients. This includes the development of more robust research methodologies, the promotion of non-pharmacological interventions, and the cautious application of pharmacological treatments with comprehensive patient education and monitoring.

FOOTNOTES

Author contributions: Wu S wrote the main manuscript; Qiu CJ performed data collection; All authors analyzed and interpreted results, reviewed the results and approved the final version of the manuscript, and were informed of each step of manuscript processing including submission, revision, revision reminder, etc.

Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: China

ORCID number: Chang-Jian Qiu 0009-0008-2657-1537.

S-Editor: Li L L-Editor: Filipodia P-Editor: Zhang XD

REFERENCES

- Celli B, Fabbri L, Criner G, Martinez FJ, Mannino D, Vogelmeier C, Montes de Oca M, Papi A, Sin DD, Han MK, Agusti A. Definition and 1 Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision. Am J Respir Crit Care Med 2022; 206: 1317-1325 [PMID: 35914087 DOI: 10.1164/rccm.202204-0671PP]
- Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS, Farzadfar F. Global prevalence of chronic obstructive pulmonary disease: 2 systematic review and meta-analysis. East Mediterr Health J 2019; 25: 47-57 [PMID: 30919925 DOI: 10.26719/emhj.18.014]
- 3 López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology 2016; 21: 14-23 [PMID: 26494423 DOI: 10.1111/resp.12660]
- Fang L, Gao P, Bao H, Tang X, Wang B, Feng Y, Cong S, Juan J, Fan J, Lu K, Wang N, Hu Y, Wang L. Chronic obstructive pulmonary 4 disease in China: a nationwide prevalence study. Lancet Respir Med 2018; 6: 421-430 [PMID: 29650407 DOI: 10.1016/S2213-2600(18)30103-6]



- Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 5 2001; 68: 4-19 [PMID: 11223724 DOI: 10.1159/000050456]
- Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory health and disease. Lancet Respir Med 2013; 1: 728-6 742 [PMID: 24429276 DOI: 10.1016/S2213-2600(13)70118-8]
- 7 Carlin BW. COPD and associated comorbidities: a review of current diagnosis and treatment. Postgrad Med 2012; 124: 225-240 [PMID: 22913911 DOI: 10.3810/pgm.2012.07.2582]
- Janahi IA, Rehman A, Baloch NU. Corticosteroids and Their Use in Respiratory Disorders. In: Al-kaf AG, editor. Corticosteroids. 8 IntechOpen, 2018 [DOI: 10.5772/intechopen.72147]
- Griffith MF, Chen HP, Bekelman DB, Feemster LC, Spece LJ, Donovan LM, Au DH, Carey EP. Comorbid Anxiety and Depression, Though 9 Underdiagnosed, Are Not Associated with High Rates of Low-Value Care in Patients with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2021; 18: 442-451 [PMID: 33306930 DOI: 10.1513/AnnalsATS.201912-8770C]
- 10 Kowalczys A, Bohdan M, Wilkowska A, Pawłowska I, Pawłowski L, Janowiak P, Jassem E, Lelonek M, Gruchała M, Sobański P. Comprehensive care for people living with heart failure and chronic obstructive pulmonary disease-Integration of palliative care with diseasespecific care: From guidelines to practice. Front Cardiovasc Med 2022; 9: 895495 [PMID: 36237915 DOI: 10.3389/fcvm.2022.895495]
- Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden 11 of Disease study. J Psychiatr Res 2020; 126: 134-140 [PMID: 31439359 DOI: 10.1016/j.jpsychires.2019.08.002]
- Zareifopoulos N, Bellou A, Spiropoulou A, Spiropoulos K. Prevalence, Contribution to Disease Burden and Management of Comorbid 12 Depression and Anxiety in Chronic Obstructive Pulmonary Disease: A Narrative Review. COPD 2019; 16: 406-417 [PMID: 31638445 DOI: 10.1080/15412555.2019.1679102]
- Chetty U, McLean G, Morrison D, Agur K, Guthrie B, Mercer SW. Chronic obstructive pulmonary disease and comorbidities: a large cross-13 sectional study in primary care. Br J Gen Pract 2017; 67: e321-e328 [PMID: 28450344 DOI: 10.3399/bjgp17X690605]
- 14 Dua R, Das A, Kumar A, Kumar S, Mishra M, Sharma K. Association of comorbid anxiety and depression with chronic obstructive pulmonary disease. Lung India 2018; 35: 31-36 [PMID: 29319031 DOI: 10.4103/lungindia.lungindia 537 16]
- Chaudhary SC, Nanda S, Tripathi A, Sawlani KK, Gupta KK, Himanshu D, Verma AK. Prevalence of psychiatric comorbidities in chronic 15 obstructive pulmonary disease patients. Lung India 2016; 33: 174-178 [PMID: 27051106 DOI: 10.4103/0970-2113.177441]
- Santos NCD, Miravitlles M, Camelier AA, Almeida VDC, Maciel RRBT, Camelier FWR. Prevalence and Impact of Comorbidities in 16 Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review. Tuberc Respir Dis (Seoul) 2022; 85: 205-220 [PMID: 35618259 DOI: 10.4046/trd.2021.0179]
- Moisieieva NV, Burya LV, Kapustianskaya AA, Kolenko IA, Rumyantseva MA, Shumeiko OH. Comprehensive patterns of comorbidity: copd 17 and depression. Aspects of treatment. Wiad Lek 2018; 71 (3 pt 1): 588-591 [PMID: 29783230]
- 18 Badr H, Federman AD, Wolf M, Revenson TA, Wisnivesky JP. Depression in individuals with chronic obstructive pulmonary disease and their informal caregivers. Aging Ment Health 2017; 21: 975-982 [PMID: 27212642 DOI: 10.1080/13607863.2016.1186153]
- Thapa N, Maharjan M, Shrestha TM, Gauchan S, Pun P, Thapa YB. Anxiety and depression among patients with chronic obstructive 19 pulmonary disease and general population in rural Nepal. BMC Psychiatry 2017; 17: 397 [PMID: 29233103 DOI: 10.1186/s12888-017-1550-5]
- Husain MO, Chaudhry IB, Blakemore A, Shakoor S, Husain MA, Lane S, Kiran T, Jafri F, Memon R, Panagioti M, Husain N. Prevalence of 20 depression and anxiety in patients with chronic obstructive pulmonary disease and their association with psychosocial outcomes: A crosssectional study from Pakistan. SAGE Open Med 2021; 9: 20503121211032813 [PMID: 34659761 DOI: 10.1177/20503121211032813]
- Bratek A, Zawada K, Beil-Gawełczyk J, Beil S, Sozańska E, Krysta K, Barczyk A, Krupka-Matuszczyk I, Pierzchała W. Depressiveness, 21 symptoms of anxiety and cognitive dysfunctions in patients with asthma and chronic obstructive pulmonary disease (COPD): possible associations with inflammation markers: a pilot study. J Neural Transm (Vienna) 2015; 122 Suppl 1: S83-S91 [PMID: 24532256 DOI: 10.1007/s00702-014-1171-9
- Gold SM, Köhler-Forsberg O, Moss-Morris R, Mehnert A, Miranda JJ, Bullinger M, Steptoe A, Whooley MA, Otte C. Comorbid depression in 22 medical diseases. Nat Rev Dis Primers 2020; 6: 69 [PMID: 32820163 DOI: 10.1038/s41572-020-0200-2]
- Lotfaliany M, Bowe SJ, Kowal P, Orellana L, Berk M, Mohebbi M. Depression and chronic diseases: Co-occurrence and communality of risk 23 factors. J Affect Disord 2018; 241: 461-468 [PMID: 30149333 DOI: 10.1016/j.jad.2018.08.011]
- 24 Zysman M, Raherison-Semjen C. Women's COPD. Front Med (Lausanne) 2021; 8: 600107 [PMID: 35047517 DOI: 10.3389/fmed.2021.600107
- Shapero BG, Cassano P, Papakostas GI, Fava M, Stern TA. Depressed patients. 7th ed. In: Stern TA, Freudenreich O, Smith FA, Fricchione 25 GL, Rosenbaum JF, editors. Massachusetts General Hospital Handbook of General Hospital Psychiatry. Elsevier, 2017: 69
- Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis 26 2014; 9: 871-888 [PMID: 25210449 DOI: 10.2147/COPD.S49621]
- Nemani K, Li C, Olfson M, Blessing EM, Razavian N, Chen J, Petkova E, Goff DC. Association of Psychiatric Disorders With Mortality 27 Among Patients With COVID-19. JAMA Psychiatry 2021; 78: 380-386 [PMID: 33502436 DOI: 10.1001/jamapsychiatry.2020.4442]
- Song CY, Liu X, Wang YQ, Cao HP, Yang Z, Ma RC, Yin YY, Xie J. Effects of home-based telehealth on the physical condition and 28 psychological status of patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Int J Nurs Pract 2023; 29: e13062 [PMID: 35545098 DOI: 10.1111/ijn.13062]
- 29 Lokesh KS, Rao AA, Chaya SK, Jayaraj BS, Praveena AS, Krishna M, Madhivanan P, Padukudru Anand M. Associations of Vitamin D, chronic obstructive pulmonary disease and acute exacerbations of COPD with anxiety and depression: a nested case control study. Wellcome *Open Res* 2022; 7: 86 [DOI: 10.12688/wellcomeopenres.17439.1]
- 30 Wu D, Zhao X, Huang D, Dai Z, Chen M, Li D, Wu B. Outcomes associated with comorbid anxiety and depression among patients with stable COPD: A patient registry study in China. J Affect Disord 2022; 313: 77-83 [PMID: 35760193 DOI: 10.1016/j.jad.2022.06.059]
- Cao Y, Li P, Wang Y, Liu X, Wu W. Diaphragm Dysfunction and Rehabilitation Strategy in Patients With Chronic Obstructive Pulmonary 31 Disease. Front Physiol 2022; 13: 872277 [PMID: 35586711 DOI: 10.3389/fphys.2022.872277]
- Atlantis E, Fahey P, Cochrane B, Smith S. Bidirectional associations between clinically relevant depression or anxiety and COPD: a 32 systematic review and meta-analysis. Chest 2013; 144: 766-777 [PMID: 23429910 DOI: 10.1378/chest.12-1911]
- Pooler A, Beech R. Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: 33 a systematic review. Int J Chron Obstruct Pulmon Dis 2014; 9: 315-330 [PMID: 24729698 DOI: 10.2147/COPD.S53255]
- Mao W, Shalaby R, Owusu E, Elgendy HE, Agyapong B, Eboreime E, Silverstone P, Chue P, Li XM, Vuong W, Ohinmaa A, Taylor V, 34



Greenshaw AJ, Agyapong VIO. Depression, anxiety, and poor well-being at discharge from psychiatric hospitals: prevalence and risk factors. Front Psychiatry 2024; 15: 1408095 [PMID: 39056021 DOI: 10.3389/fpsyt.2024.1408095]

- 35 Mathew AR, Yount SE, Kalhan R, Hitsman B. Psychological Functioning in Patients With Chronic Obstructive Pulmonary Disease: A Preliminary Study of Relations With Smoking Status and Disease Impact. Nicotine Tob Res 2019; 21: 686-690 [PMID: 29788395 DOI: 10.1093/ntr/nty102]
- Witcraft SM, Dixon LJ, Leukel P, Lee AA. Anxiety sensitivity and respiratory disease outcomes among individuals with chronic obstructive 36 pulmonary disease. Gen Hosp Psychiatry 2021; 69: 1-6 [PMID: 33444938 DOI: 10.1016/j.genhosppsych.2020.12.004]
- Rahi MS, Thilagar B, Balaji S, Prabhakaran SY, Mudgal M, Rajoo S, Yella PR, Satija P, Zagorulko A, Gunasekaran K. The Impact of Anxiety 37 and Depression in Chronic Obstructive Pulmonary Disease. Adv Respir Med 2023; 91: 123-134 [PMID: 36960961 DOI: 10.3390/arm910200111
- Jang SM, Kim KU, Na HJ, Song SE, Lee SH, Lee H, Kim YS, Lee MK, Park HK. Depression is a major determinant of both disease-specific 38 and generic health-related quality of life in people with severe COPD. Chron Respir Dis 2019; 16: 1479972318775422 [PMID: 29742914 DOI: 10.1177/1479972318775422]
- Ko FWS, Chan KP, Hui DSC. Comprehensive care for chronic obstructive pulmonary disease. J Thorac Dis 2019; 11: S2181-S2191 [PMID: 39 31737345 DOI: 10.21037/jtd.2019.09.81]
- Grassi L, Caruso R, Riba MB, Lloyd-Williams M, Kissane D, Rodin G, McFarland D, Campos-Ródenas R, Zachariae R, Santini D, Ripamonti 40 CI; ESMO Guidelines Committee. Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline. ESMO Open 2023; 8: 101155 [PMID: 37087199 DOI: 10.1016/j.esmoop.2023.101155]
- Khamboon T, Pakanta I. Intervention for Symptom Cluster Management of Fatigue, Loss of Appetite, and Anxiety among Patients with Lung 41 Cancer undergoing Chemotherapy. Asia Pac J Oncol Nurs 2021; 8: 267-275 [PMID: 33850960 DOI: 10.4103/2347-5625.311003]
- Anjum A. Measuring the Effectiveness of Antidepressant Treatment By Implementing Beck's Depression Inventory (BDI). Doctoral 42 dissertations, University of San Diego. 2023 [DOI: 10.22371/07.2023.015]
- Hollingworth W, Fawsitt CG, Dixon P, Duffy L, Araya R, Peters TJ, Thom H, Welton NJ, Wiles N, Lewis G; PANDA Team. Cost-43 Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT. Pharmacoecon Open 2020; 4: 427-438 [PMID: 31777008 DOI: 10.1007/s41669-019-00188-5]
- He Y, Zheng Y, Xu C, Yang H, Wang Z, Zhou L, Wan Y, Zheng D, Zhu J. Sertraline hydrochloride treatment for patients with stable chronic 44 obstructive pulmonary disease complicated with depression: a randomized controlled trial. Clin Respir J 2016; 10: 318-325 [PMID: 25308771 DOI: 10.1111/crj.12219]
- Yohannes AM, Alexopoulos GS. Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: 45 impact on the course of the disease and health outcomes. Drugs Aging 2014; 31: 483-492 [PMID: 24902934 DOI: 10.1007/s40266-014-0186-0]
- Usmani ZA, Carson-Chahhoud KV, Esterman AJ, Smith BJ. A randomized placebo-controlled trial of paroxetine for the management of 46 anxiety in chronic obstructive pulmonary disease (PAC Study). J Multidiscip Healthc 2018; 11: 287-293 [PMID: 29983572 DOI: 10.2147/JMDH.S166022]
- Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 2013; 47: 1330-1341 [PMID: 47 24259697 DOI: 10.1177/1060028013501994]
- 48 Martland R, Mondelli V, Gaughran F, Stubbs B. Can high intensity interval training improve health outcomes among people with mental illness? A systematic review and preliminary meta-analysis of intervention studies across a range of mental illnesses. J Affect Disord 2020; 263: 629-660 [PMID: 31780128 DOI: 10.1016/j.jad.2019.11.039]
- Varkonyi-Sepp J, Freeman A, Ainsworth B, Kadalayil LP, Haitchi HM, Kurukulaaratchy RJ. Multimorbidity in Difficult Asthma: The Need 49 for Personalised and Non-Pharmacological Approaches to Address a Difficult Breathing Syndrome. J Pers Med 2022; 12: 1435 [PMID: 36143220 DOI: 10.3390/jpm12091435]



WJP https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

